SIREN : 483657524
IMPAC INGENIERIE PHARMA is a French company founded 20 years ago, specialized in the sector Ingénierie, études techniques. Based in PARIS (75014), this company of category PME shows in 2022 a revenue of 8.6 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-04-18
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/C | N/C | 8 569 167 € | N/C | 6 573 667 € | 6 915 605 € | N/C | N/C | N/C |
| Net income | 20 414 € | 81 441 € | 163 712 € | 138 918 € | 191 679 € | 154 508 € | 136 786 € | 122 508 € | 118 339 € |
| EBITDA | N/C | N/C | 252 180 € | N/C | 276 149 € | 270 994 € | N/C | N/C | N/C |
| Net margin | N/C | N/C | 1.9% | N/C | 2.9% | 2.2% | N/C | N/C | N/C |
In 2024, IMPAC INGENIERIE PHARMA generates positive net income of 20 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 118 k€ -> 20 k€.
20 414 €
The debt ratio (= Financial debt / Equity x 100) stands at 9%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 58%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
8.555%
57.584%
In 2024, the debt ratio of IMPAC INGENIERIE PHARMA (8.55) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of IMPAC INGENIERIE PHARMA (57.6%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2022, the repayment capacity of IMPAC INGENIERIE PHARMA (2.14) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 280.27. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
280.271
In 2024, the liquidity ratio of IMPAC INGENIERIE PHARMA (280.27) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
In 2022, the interest coverage of IMPAC INGENIERIE PHARMA (4.3x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
0 €
0 j
0 j
0 j
Indicative estimate only : the number of comparable transactions in this sector is limited (40 transactions). This range of 3 615€ to 41 883€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 40 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare IMPAC INGENIERIE PHARMA with other companies in the same sector:
Voir toutes les statistiques du secteur Ingénierie, études techniques
The revenue of IMPAC INGENIERIE PHARMA in 2022 is 8.6 M€.
Yes, IMPAC INGENIERIE PHARMA generated a net profit of 20 k€ in 2024.
The headquarters of IMPAC INGENIERIE PHARMA is located in PARIS (75014), in the department Paris.
The tax return of IMPAC INGENIERIE PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
IMPAC INGENIERIE PHARMA operates in the sector Ingénierie, études techniques (NAF code 71.12B). See the 'Sector positioning' section above to compare the company with its competitors.